1 Summary (150 Words)

- 2 In 2022 the World Health Organization declared a Public Health Emergency for an outbreak of mpox,
- 3 the zoonotic Orthopoxvirus (OPV) affecting at least 103 non-endemic locations world-wide. Serologic
- 4 detection of mpox infection is problematic, however, due to considerable antigenic and serologic cross-
- 5 reactivity among OPVs and smallpox-vaccinated individuals. In this report, we developed a high-
- 6 throughput multiplex microsphere immunoassay (MIA) using a combination of mpox-specific peptides
- 7 and cross-reactive OPV proteins that results in the specific serologic detection of mpox infection with
- 8 93% sensitivity and 98% specificity. The New York State Non-Vaccinia Orthopoxvirus Microsphere
- 9 Immunoassay is an important diagnostic tool to detect subclinical mpox infection and understand the
- 10 extent of mpox spread in the community through retrospective analysis.

Development of a Novel Serological Assay for the Detection of Mpox Infection in Vaccinated Populations

Jennifer L. Yates^{1,2}, Danielle T. Hunt¹, Karen E. Kulas¹, Karen Chave¹, Linda Styer^{1,2}, Sandhya T.
Chakravarthi¹, Gianna Y. Cai^{11,14}, Maria C. Bermúdez-González^{8,11}, Giulio Kleiner^{8,11}, Deena Altman⁹,
Komal Srivastava^{8,11}, the PVI study group^{8,11}, Viviana Simon^{8,9,10,11,12}, Dennis Feihel^{6,7}, Joseph
McGowan^{6,7}, Wayne Hogrefe⁵, Philip Noone⁵, Christina Egan^{1,2}, Mark K. Slifka^{3,4}, and William T. Lee^{1,2}

17

¹ Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany,

- 19 NY, USA; ²Biomedical Sciences, The School of Public Heath, The University at Albany, Albany, NY,
- 20 USA; ³Oregon National Primate Research Center, Oregon Health and Science University, Beaverton,
- 21 Oregon, USA; ⁴Najit Technologies, Inc., Beaverton, OR, USA; ⁵Aalto Bio Reagents, Dublin, Ireland;
- ⁶Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; ⁷Department of Medicine North
- 23 Shore University Hospital, Manhasset, NY, USA; ⁸Department of Microbiology, Icahn School of
- 24 Medicine at Mount Sinai, NY, USA; ⁹Division of Infectious Diseases, Department of Medicine, Icahn
- School of Medicine at Mount Sinai, New York; ¹⁰Department of Pathology, Molecular and Cell Based
 Medicine, Icahn School of Medicine at Mount Sinai, NY; ¹¹Center for Vaccine Research and Pandemic
- Medicine, Icahn School of Medicine at Mount Sinai, NY; ¹¹Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, NY, USA; ¹²The Global Health and Emerging
- 28 Pathogens Institute, Icahn School of Medicine at Mount Sinai, NY, USA
- 29
- 30 Correspondence: jennifer.yates@health.ny.gov
- 31
- 32 PVI study group (in alphabetical order): Angela A. Amoako, Dalles Andre, Harm van Bakel, Christian
- 33 Cognini, Charles R. Gleason, Ana Gonzalez-Reiche, Morgan van Kesteren, Al Lugo, Neko Lyttle, Jacob
- 34 D. Mauldin, Brian C. Monahan, Jessica R. Nardulli, Annika Oostenink, Alberto Paniz-Monodolfi, Jose
- 35 Polanco, Juan David Ramírez, Aria Rooker, and Emilia Mia Sordillo.

36 Introduction

37 Mpox (formerly known as monkeypox), is a zoonotic orthopoxvirus (OPV) that has historically 38 been endemic and largely isolated to western and central Sub-Saharan Africa ^{1, 2}. Other species of 39 OPVs include cowpox (CPXV), vaccinia (VAC; smallpox vaccine), and variola virus (VAR; smallpox) 40 which all share a high degree of genetic homology. Mpox can be transmitted through close contact with 41 an infected person or animal, bodily fluids, respiratory secretions, or consumption of contaminated 42 meat. Symptoms of infection can be severe and may include lymphadenopathy, fever, headache, 43 fatigue, muscle aches, flu-like symptoms, and a characteristic rash, and death^{3, 4}. In 2003 a non-44 endemic mpox outbreak occurred in the United States due to the importation of infected animals. In 45 total, 71 cases of mpox were detected over 5 months. The outbreak was contained through the implementation of multiple public-health efforts including restrictions placed on the movement of exotic 46 47 animals⁵. In 2022 the world faced a multi-country outbreak of non-endemic mpox, prompting the World Health Organization to announce a Public Health Emergency of International Concern. To date, over 48 49 85,000 cases with 97 deaths have been reported globally with over 30,000 of those cases and 32 50 deaths occurring in the United States. In contrast to the 2003 outbreak human-to-human transmission 51 has been the primary mode of viral spread in 2022. The size and geographic distribution of the current 52 mpox outbreak has highlighted the need for specific tools to diagnose, treat, and monitor immunity to 53 OPVs.

54 OPVs are large dsDNA viruses that encode up to 200 highly conserved viral proteins resulting in 55 extensive antigenic and serologic cross-reactivity between members of the OPV genus⁶. The protection 56 afforded by vaccination with VAC against fatal smallpox infection is based, and dependent on the 57 antigenic cross-reactivity between VAC and VAR. In the United States, childhood vaccination with VAC 58 was customary until 1972, and VAC vaccination was reinstated for the US military forces in 2002 59 resulting in a significant number of US residents with VAC-reactive antibodies^{7,8}. More recently, 60 JYNNEOS vaccine (Modified Vaccinia Ankara, Bavarian Nordic) has been administered to individuals deemed to be at high risk for mpox infection. Therefore, the development of a specific serologic assay 61 62 to monitor mpox infection is complicated by the vaccination efforts for both smallpox and mpox⁹. The 63 current serological assay available to detect the presence of OPV-specific antibodies is an ELISA with formalin-inactivated VAC used as the coating antigen¹⁰⁻¹². The advantage of a whole-virus assay is the 64 65 breadth of OPV antigens available for antibody binding – resulting in a highly sensitive assay. However, the distinct disadvantage of a whole-virus ELISA is the lack of specificity between OPV species which 66 67 may give false-positive results for anyone who has received VAC vaccination. Currently, there is no 68 approved serology assay that can discriminate between the antibodies produced following vaccination 69 with VAC versus those mounted upon mpox infection. Therefore, we leveraged a multiplexed

microsphere immunoassay (MIA) platform with the goal of maintaining OPV antigenic breadth while simultaneously gaining specificity to mpox and other non-vaccinia OPVs. In the present study, we created an algorithm using two mpox-specific peptides and 5 cross-reactive OPV antigens that detects IgG antibodies associated mpox infection with 93% sensitivity and 98% specificity. Our data support the use of serology as an important diagnostic tool for mpox infections, and as an mpox surveillance tool within vaccinated populations.

76

77 Results

78 Evaluation of Non-Vaccinia Peptides for the Specific Serologic Detection of Mpox Exposure

79 B21/22R is an immunomodulatory protein present in both mpox and VAR yet absent in VAC. 80 thus allowing for serologic distinction between VAC vaccination and mpox infection^{13, 14}. Dubois et al. 81 previously reported a peptide-based ELISA using 30-mer peptides optimized for the diagnostic 82 detection of mpox infection in populations that may include VAC vaccinated individuals. The authors 83 reported >90% sensitivity and >90% specificity for mpox infection using 4 BSA-conjugated peptides 84 derived from mpox (B21R-A and -B) and VAR (B22R-A and -B) in a relatively small number of mpox-85 positive and -negative subjects¹⁵. We sought to evaluate efficacy of these previously validated peptides 86 for the diagnosis of mpox infection on our high-throughput MIA on the Luminex platform. BSA-87 conjugated peptides, as described in Dubois et al. were coupled to fluorescent microspheres and 88 evaluated for IgG reactivity in the mpox-confirmed, mpox-negative, and vaccine control cohorts. 89 Receiver Operatory Characteristic (ROC) analysis revealed moderate predictive accuracy of mpox 90 infection for mpox-derived B21R-A and -B with an area under the curve (AUC) of 0.86 and 0.85. 91 respectively. In contrast, VAR-derived peptides B22R-A and -B showed lower predictive accuracy for 92 mpox infection with AUCs of 0.52 and 0.77, respectively (Figure 1a; Supplemental Table 1) and were 93 eliminated from the diagnostic assay. Based on the sensitivity/specificity calculations generated by the 94 ROC curve, we calculated clinical cutoff values for mpox peptides B21R-A and -B. Briefly, a Youden's J index (J = sensitivity + specificity -1) was calculated for the range of MFI values in the ROC analysis. 95 96 The clinical cutoff was set as the MFI equaling the highest Youden's J index which is equal to the best 97 balance of specificity and sensitivity over the range of the assay (**Supplemental Table 1**).

To visualize the baseline binding IgG reactivity to B21R-A and -B in mpox-negative donors and recent vaccinees compared to mpox confirmed donors, we plotted the log10 MFI for individual donors grouped by cohort as described in Table 1. As routine smallpox vaccination with VAC ended in the United States in 1972, consideration of birth year allowed us to estimate the childhood vaccination status of each donor in the mpox-negative cohort⁸. Therefore, mpox-negative donors were divided into "presumed naïve" and "childhood vaccination" groups based on birth year post- or pre-1972. The

104 average MFI for the mpox-confirmed donors was significantly higher than the presumed naïve, 105 childhood vaccination, and recent vaccinee groups for both B21R-A and -B (Figure 1b). However, a 106 considerable number of mpox-negative donors show peptide-specific IgG reactivity above the clinical 107 cutoff despite the lack of mpox exposure. Importantly, the childhood and recent vacinee groups did not 108 show higher levels of B21R-A or -B reactivity than the presumed naïve donors indicating that smallpox 109 vaccination does not contribute to non-specific IgG reactivity to B21R-A and -B in mpox negative 110 populations. Since up to 57% of mpox cases reported in the 2022 outbreak have been in HIV-positive 111 individuals¹⁶ we included 142 plasma or serum samples sent to the Wadsworth Center for HIV 112 confirmatory testing in our mpox-negative cohort. HIV+ donors from the mpox-negative cohort showed 113 a significantly higher MFI as compared to donors without HIV infection (Figure 1c). When considered 114 together, the specificity of peptides B21R-A and -B (67%; Supplemental Table 1) is insufficient for the 115 development of a robust mpox-specific serological assay.

116

117 Evaluation of OPV Antigens for the Serologic Detection of Mpox Exposure

118 We asked whether any naturally cross-reactive recombinant proteins derived from VAC or mpox 119 could aid in the development of an mpox-specific serologic assay. The predictive accuracy of different 120 OPV antigens for the detection of mpox infection was tested with a variety of VAC and mpox-derived 121 protein antigens that were available through a public repository, in-house production, or commercial 122 vendors. Recombinant proteins VAC A27L. mpox A29L. VAC A33R. mpox A35R. VAC B5R. VAC L1R. 123 and mpox H3L were tested for IgG antibody reactivity using the same mpox-infection confirmed and 124 mpox-negative samples as described in Figure 1 (Figure 2a). ROC analysis of each antigen revealed 125 distinct differences in the predictive accuracy for mpox infection. VAC A33R, mpox A35R, VAC B5R, 126 VAC L1R and mpox H3L showed moderate to excellent predictive accuracy with AUC values above 127 0.80¹⁷. In contrast, VAC A27L and homologous mpox A29L showed low predictive accuracy with AUCs 128 below 0.80 and were removed from the assay. As with the mpox-specific peptides, clinical cutoffs were 129 calculated for the remaining antigens using the Youden's J index calculated from the ROC analysis.

130 To visualize the baseline binding IgG reactivity to VAC A33R, mpox A35R, VAC B5R, VAC L1R, 131 and mpox H3L in mpox-negative donors and recent vaccinees as compared to mpox confirmed donors. 132 we plotted the log10 MFI for individual donors grouped by cohort as described in Figure 1. The average 133 MFI of the mpox-confirmed donors for each recombinant antigen was significantly higher than the MFI's 134 for the mpox-negative presumed naïve and childhood vaccination groups. As expected, the childhood 135 vaccination group had significantly higher average MFI's than the presumed naïve group indicating 136 previous exposure to VAC antigens and durable humoral memory from childhood smallpox vaccination 137 ^{14, 18} (Figure 2b). Although not statistically significant, the average MFI of recent vaccinees trended

higher than the childhood vaccination group across all recombinant antigens. These data show that
 mpox infection can induce a more robust antibody response than vaccinia vaccination, which may be
 exploited for the development of a diagnostic serology assay.

141

142 Distinct Pattern of IgG Reactivity to OPV Antigens and Mpox-specific Peptides Between Mpox-

143 confirmed and Mpox-negative Donors

144 We asked whether multiplexing multiple antigens would reveal patterns of serological reactivity 145 that may be used to distinguish between VAC vaccination and mpox infection. To this end, we plotted 146 each specimen/antigen combination on a heat map to visualize the pattern of reactivity in the mpox-147 confirmed and mpox-negative cohorts. The mpox-confirmed donors showed uniform and simultaneous 148 reactivity to the mpox peptides and the OPV antigens that were tested (Figure 3). In contrast, the 149 mpox-negative presumed naïve group showed sporadic reactivity to the mpox peptides and OPV 150 antigens. Here, individuals that showed positive reactivity to the B21R peptides did not show 151 simultaneous reactivity with the OPV antigens. The mpox-negative childhood vaccination group 152 displayed an increased frequency of antigen reactivity as expected with previous exposure to VAC, yet 153 rarely showed simultaneous reactivity to the mpox peptides and OPV antigens. Recent vaccinees 154 displayed a similar pattern of mpox peptide and OPV antigen reactivity to the childhood vaccination 155 group. The differential patterns of antigen reactivity between mpox-confirmed and mpox-negative 156 cohorts suggest a combination of OPV antigens and mpox-specific peptides may provide specific 157 serologic detection of mpox infection.

158

159 Development of an Algorithm for the Specific Detection of Mpox Infection

160 With the goal of developing an algorithm for a mpox-specific assay we counted the number of 161 clinically reactive (MFI above the clinical cutoff) OPV antigens for every individual in the mpox-162 confirmed and -negative cohorts. Donors from the mpox-confirmed cohort were simultaneously reactive 163 for at least 3 OPV antigens, with a median count of 4 antigens (Figure 4a). In contrast, presumed 164 naïve donors from the mpox-negative cohort were rarely reactive for 1 OPV antigen with a median 165 count of 0 antigens. Mpox-negative donors from the childhood vaccination and recent vaccinee groups 166 showed a range of reactivity from 0 to 4 OPV antigens with median counts of 0 and 2.0, respectively. 167 Setting a clinical cutoff of 3 or more reactive antigens captures 98% of the mpox-confirmed donors 168 while excluding 95% of the mpox-negative cohort.

Based on the high antibody reactivity of mpox-infected donors to both cross reactive OPV antigens and the mpox-specific peptides, we developed a two-tiered algorithm designed to remove individuals without true mpox infection from further analysis (**Figure 4b**). First, the total number of

172 reactive (MFI ≥ cutoff) OPV antigens (A33/35R, B5R, L1R, H3L) was counted for each individual donor. 173 Donors with less than 3 reactive OPV antigens will automatically be considered negative (non-reactive; 174 NR) for mpox-infection. Donors with 3 or more reactive OPV antigens will be considered for the next 175 step of the algorithm. At this stage 95% of the mpox-negative donors (n=341) have been labeled NR 176 and removed from the analysis, while 98% of the mpox-infected cohort will move to the next tier of the 177 algorithm. Next, donors that "passed" the first step of the algorithm will be considered for IgG reactivity 178 to the mpox-specific peptides B21R-A and -B. Finally, donor samples that are reactive (MFI ≥ cutoff) for 179 one or both peptides will be considered positive (reactive: R) for mpox infection. After the second step 180 of the algorithm 37 out of 40 patients from the mpox-confirmed cohort have been labelled R. giving our 181 diagnostic test (New York State Orthopoxvirus Non-Vaccinia Virus Microsphere Immunoassay for IgG 182 Antibody Detection; NYS-OPV-MIA) 93% (95%CI = 80-97%) sensitivity for mpox infection with an 183 overall specificity of 98% (95%CI = 96-99%) (**Table 3**). It is important to note that assay specificity is 184 different depending on the test population. When testing vaccinated donors assay specificity is 94% 185 (95%CI = 88-97%) for the childhood vaccinee group, and 93% (95%CI = 88-96%) when the recent 186 vaccinees are added to the calculation. However, the NYS-OPV-MIA is highly (100%; 98-100%) 187 specific when testing unvaccinated individuals under 50 years of age. As part of assay validation we 188 also tested a specificity panel of 115 serum specimens with known antibodies to a diverse group of 189 bacterial and viral pathogens, as well as anti-nuclear antibodies (ANA) and rheumatoid factor (RF) 190 (Supplemental Table 1). The specificity panel included specimens from infections that may be confused 191 with mpox, including Syphilis (n=8), Herpes Simplex Virus (HSV; n = 15), and Varicella Zoster (n = 18). 192 When combined with the mpox-negative cohort (n = 456) the specificity of the NYS-OPV-MIA remains 193 at 98% (95%CI = 96-99%). In summary, we have developed a robust serological assay with high 194 sensitivity and high specificity to aid in the diagnosis of mpox-infection.

195

196 Strength of Mpox Antigen Binding is Dictated by the First Viral Exposure

197 The induction of potent cross-protective immunity through vaccinia virus vaccination for 198 protection against smallpox is well established^{19, 20}. There is also strong evidence for VAC vaccination 199 to provide some degree of protection against mpox infection^{21, 22}. Our mpox serology assay includes the 200 homologous proteins A33/35R from both VAC and mpox respectively, which allowed us to ask how 201 previous exposure to VAC through vaccination influences antibody binding following mpox infection. To 202 this end, we divided the mpox cohort by birth year to reflect the childhood vaccination status of the 203 mpox-positive cohort. When considering IgG binding to VAC A33R, mpox-infected patients bind equally 204 well to VAC A33R regardless of previous VAC exposure. In contrast, mpox-infected patients under 50 205 trended toward higher binding to mpox A35R as compared to their previously vaccinated counterparts

206 (Figure 4c). To estimate the relative binding of VAC A33R versus mpox A35R in each antigen 207 exposure group we calculated a binding ratio by dividing the IgG MFI of VAC A33R by the IgG MFI of 208 mpox A35R. The resulting data revealed differential binding of the A33/35R homologues based on the 209 primary immunizing virus. The vaccine control group showed the highest VAC/mpox binding ratio 210 indicating that antibodies from this group bound the VAC A33R protein better than the mpox 211 homologue. In contrast, previously unvaccinated mpox-infected patients showed the lowest binding 212 ratio, indicating better antibody binding to mpox A35R rather than the VAC homologue. Interestingly, 213 previously vaccinated mpox-infected patients showed an intermediate A33/35R binding ratio suggesting 214 a contribution from both VAC-derived and mpox-derived antibodies to the overall binding profile in 215 these patients. Together these data demonstrate the presence of distinct epitopes in homologous 216 proteins despite high levels of cross-reactivity, and that original antigenic sin may play a role in the 217 humoral response to mpox in previously vaccinated individuals.

218

219 Discussion

In response to a Public Health Emergency of International Concern, we developed a sensitive (93%) and specific (98%) multiplex MIA for the differential serologic detection of mpox infection in VAC vaccinated populations. The assay contains 2 mpox-specific peptides and 5 cross-reactive OPV recombinant proteins derived from either VAC or mpox. Here, we leveraged both multiplex technology and the differential antibody reactivity profiles resulting from VAC vaccination and mpox infection to build specificity into our serologic assay.

226 In 2012 Slifka and colleagues reported a highly sensitive mpox-specific ELISA based on 30-mer 227 peptides derived from the B21/22R gene that is present in mpox yet absent in VAC¹⁵. We tested the 228 BSA-conjugated B21/22R peptides on our multiplex MIA as a high-throughput alternative to the 229 previously described ELISA. Of the four peptides tested, mpox-derived B21R-A and -B had the best 230 discriminatory capacity for mpox infection, where VAR-derived B22R-A and -B were comparatively 231 poor. In contrast to the Dubois-Slifka study, we found extensive non-specific IgG reactivity to the 232 peptides in an mpox-negative population, the origin of which is unknown. The most likely explanation 233 for the discrepant specificity between studies is the size and composition of our negative cohort. The 234 mpox-negative cohort of the Dubois-Slifka study was composed of 20 healthy naïve, recently 235 vaccinated, and childhood vaccinated donors for a total of 60 test subjects. Here, we calculated 236 diagnostic specificity of the B21/22R peptides based on a negative cohort of 341 donors, 142 of which 237 were HIV-positive. A thorough analysis of our mpox-negative cohort revealed that much of the non-238 specific reactivity seen to the peptides was present in the samples collected from people living with 239 HIV. In fact, non-specific serologic reactivity in HIV+ populations due to polyclonal B cell activation and

hypergammaglobulinemia is a well-characterized aspect of HIV infection^{23, 24}. Further, many HIV-1specific broadly neutralizing antibodies generated during HIV infection are polyreactive²⁵. The high
frequency of HIV+ patients in the mpox test population¹⁶ has the potential to impact assay performance
and underscores the importance of considering test population demographics prior to assay
development. In addition, we clearly demonstrated that the B21/22R-derived peptides tested here had
insufficient specificity to be used as a stand-alone diagnostic assay.

246 With a lack of additional non-vaccinia derived proteins to test, we turned to immunodominant 247 VAC and mpox antigens known for their cross-reactivity across OPV species. We demonstrate that 248 mpox-infected donors have robust IgG reactivity to the immunodominant antigens A33/35R, B5R, L1R, 249 and H3L. In contrast, both recent and childhood vaccinees show detectable antibody reactivity to one or 250 more of the antigens tested, while the antibody profile of each individual lacks the magnitude and 251 antigenic breadth that is seen following mpox infection. Our data is supported by previous work 252 showing the majority of VAC vaccinees recognize a small fraction of the OPV proteins tested in a 253 protein microarray. Moreover, no single antigen in the array was universally recognized by all 254 vaccinees¹². Further, antibodies specific for immunodominant antigens A33, B5, L1, and H3 are rarely seen in all individuals following primary VAC immunization^{12, 26, 27}. The cause for reduced antibody titer 255 256 and antigenic breadth in vaccinated versus mpox infected individuals may be due to differences in viral 257 load or tropism that occur through vaccination versus infection²⁸. In fact, challenge models have shown 258 increases in both the magnitude and coverage of OPV-specific antibodies following mpox infection of 259 VAC vaccinated animals¹².

260 Serologic assays measure the host response to an infectious agent which can be detected for 261 months to years following infection. However, measuring the host immune response comes with 262 inherent challenges such as antigenic cross-reactivity and genetic variability between individuals. We 263 demonstrated that a multiplex immunoassay platform using a combination of mpox peptides and OPV 264 proteins can identify mpox infection with high sensitivity and specificity in a population where VAC 265 vaccination has occurred. Furthermore, we show that mpox infection and VAC vaccination result in 266 differential patterns of IgG reactivity that could be exploited for diagnostic detection despite high levels 267 of antigenic cross-reactivity. The bead-based platform described in this study is amenable to highthroughput processing which may be useful for performing large-scale sero-epidemiology studies²⁹ in 268 269 high-risk populations and inform our understanding of mpox transmission in the future.

270 Limitations of the Study

- 271 The B21/22R gene is present used as the final discriminator for mpox infection in our assay is
- 272 expressed in other non-vaccinia OPV species. Interpretation of our assay may be difficult in regions
- 273 where cowpox or other non-vaccinia OPVs are endemic³⁰. In addition, sequencing efforts during the
- 274 2002 mpox outbreak have identified isolates with genetic deletions that may affect the B21R gene³¹.
- 275 B21R deletions in the mpox genome have the potential to effect assay sensitivity if such mutations
- 276 were to be commonplace in circulating mpox strains.

277 Acknowledgements

- We wish to acknowledge and express our gratitude to all of the study participants for their generosity,
 without wich this study would not be possible. We acknowledge and thank the following members of the
 Diagnostic Immunology Laboratory for their expert technical assistance: Kelly Howard, Kyle Carson,
- and Theresa Lamson. We acknowledge and thank Jean Rock and Rachel Bievenue of the Bloodborne
- 282 Viruses Laboratory and Michael Perry of the Biodefense Laboratory for providing sample preparation.
- 283 We acknowledge and thank Heidi Dillenbeck for quality control and quality assurance support. We
- thank Archana Thomas of the Slifka Laboratory for assistance with sample preparation and shipping.
- 285 We thank Dr. Charles Gonzalez of the AIDS Institute, NYSDOH for facilitating serum specimen
- acquisition. We thank Nicholas J. Mantis for critical reading of the manuscript. Peptides were
- 287 manufactured and supplied by Aalto Bio Reagents, Biosynth Group.
- 288

289 Funding Sources

- 290 This (publication, journal article, etc.) was supported by Cooperative Agreement Number
- NU50CK000516 funded by the Centers for Disease Control and Prevention. Its contents are solely the
 responsibility of the authors and do not necessarily represent the official views of the Centers for
 Disease Control and Prevention or the Department of Health and Human Services. V.S. and her team
 are, in part, supported by U19AI168621 and seed funds of the Mount Sinai Vaccine Research and
 Pandemic Preparedness (c-VaRPP).
- 296

297 Author Contributions Statement

- Conceptualization, J.L.Y., W.T.L., M.K.S.; Methodology, D.T.H., J.L.Y.; Validation, D.T.H., K.E.K.;
 Formal Analysis, J.L.Y. Investigation, D.T.H., J.L.Y.; Resources, K.C., L.S., S.T.C., G.Y.C., M.C.B-
- 300 G., G.K., D.A., K.S., PVI, V.S., D.F., J.M., W.H., P.N., C.E., M.K.S.; **Data Curation**, J.L.Y., D.T.H.
- 301 Writing Original Draft, J.L.Y.; Writing Review and Editing, J.L.Y, M.K.S., W.T.L and N.J.M.;
- 302 **Visualization**, J.L.Y.; **Supervision**, W.T.L, M.K.S., and J.L.Y.
- 303
- 304 Declaration of Interests

- 305 P.K. and W.H. have a financial interest in Aalto Bio Reagents, a company that may have a commercial
- 306 interest in the results of this research and technology. OHSU and M.K.S. have a financial interest in
- 307 Najit Technologies, Inc., a company that may have a commercial interest in the results of this research
- 308 and technology. This potential individual and institutional conflict of interest has been reviewed and
- 309 managed by OHSU. The Icahn School of Medicine at Mount Sinai has filed patent applications relating
- 310 to SARS-CoV-2 serological assays, which list Viviana Simon as a co-inventor.

311 Figure Legends

312

314

313 Figure 1: Evaluation of Non-Vaccinia Peptides for the Detection of Mpox Infection

315 Serum or plasma specimens from 341 presumed mpox-negative donors and 40 mpox confirmed 316 patients were analyzed for antibody reactivity to peptide antigens derived from mpox and variola virus 317 (VAR) by a microsphere immunoassay. (A) Median fluorescence intensity (MFI) of IgG reactivity to 318 individual 31-mer peptides was used to generate ROC curves representing for mpox-derived B21R-A 319 and -B (magenta) or VAR-derived B22R-A and -B (blue). (B) The log₁₀ MFI of IgG reactivity to mpox 320 B21R-A and -B was plotted for mpox-negative, -positive, and recent vaccinee donors. The mpox-321 negative cohort was divided by birth year post- and pre-1972 to estimate smallpox childhood 322 vaccination status. (C) Log₁₀ MFI of IgG reactivity to mpox B21R-A and -B was plotted for mpox-323 negative donors post-1972 (>50) divided by "healthy" and "HIV". Each dot represents and individual 324 donor. Statistical significance was determined by the non-parametric Kruskal-Wallis test where *p < 0.05 **p < 0.001 ***p < 0.0001, and ****p < 0.00001 adjusted for multiple comparisons by Dunn's test. 325 326 327 Figure 2: IgG Antibody Reactivity to Orthopoxvirus Antigens Among Mpox Negative and 328 **Positive Cohorts** 329 Serum or plasma specimens from 341 presumed mpox-negative donors and 40 mpox confirmed

330 patients were analyzed for antibody reactivity to recombinant protein antigens derived from mpox or 331 vaccinia virus (VAC) by microsphere immunoassay. (A) Median fluorescence intensity (MFI) of IgG 332 reactivity to recombinant antigens from mpox or VAC (mpox A35R, solid magenta; VAC A33R, dashed 333 magenta; mpox H3L solid light blue; VAC B5R dashed green; VAC L1R dashed orange; mpox A29L 334 solid dark blue, VAC A27L dashed dark blue) were used to generate ROC curves used to represent the 335 sensitivity (%) and specificity (%) of each antigen to detect mpox infection. (B) Log_{10} MFI of IgG 336 reactivity to OPV antigens (A33/35, B5R, L1R, and H3L) plotted for mpox-negative, -positive, and 337 recent vaccinee donors. Each dot represents and individual donor. Statistical significance was 338 determined by the non-parametric Kruskal-Wallis test where *p < 0.05 **p < 0.001 ***p < 0.0001, and 339 ****p < 0.00001 adjusted for multiple comparisons by Dunn's test.

340

Figure 3: Pattern of OPV Antigen and Mpox Peptide IgG Reactivity Among Mpox-negative and postive Cohorts

Heat maps indicate the relative index value (MFI/cutoff value) of each antigen (Mpox A35R, VAC B5R,
VAC L1R, Mpox H3L, Mpox B21R-A, and Mpox B21R-B; vertical columns) for each serum/plasma

- donor (horizontal rows). Yellow corresponds to a negative index value (< 1.0) below the clinical cutoff.
 The level of red saturation corresponds to higher index values (> 1.0) above the clinical cutoff.
- 347

Figure 4: OPV Antigen Count and Algorithm for the Specific Serologic Detection of Mpox

349 Infection

350 (A) The number of OPV antigens (A33/35, B5R, L1R, and H3L) counted as reactive (R). Reactivity was 351 defined as an MFI value at or above the calculated clinical cutoff value. The antigen count distribution 352 was displayed as a violin plot for mpox-confirmed and mpox-negative cohorts. The mpox-negative 353 cohort divided by birth year post- (presumed naïve) and pre-1972 (Childhood VAC) to estimate 354 smallpox childhood vaccination status. (B) Serum or plasma specimens tested for mpox infection using 355 a multiplexed microsphere immunoassay will be subjected to a 2-tier algorithm using a combination of 356 mpox-specific peptides and OPV antigens. First, specimens will be considered for IgG reactivity to a set 357 of cross-reactive OPV antigens (VAC A33R, mpox A35R, VAC B5R, VAC L1R, and mpox H3L). 358 Samples with reactivity to 2 or fewer antigens will be considered non-reactive (NR; MFI < clinical cutoff) 359 overall for mpox exposure while samples that test reactive (R; MFI > clinical cutoff) to 3 or more OPV 360 antigens will move to the second tier of the algorithm. Next, samples will be considered for their 361 reactivity to mpox peptides B21R-A and -B. Samples with no peptide reactivity will be considered NR 362 for mpox infection. Samples with reactivity to one or more mpox peptides will be considered R for mpox 363 infection. (C) Serum specimens from mpox-confirmed donors (n=40) and recent vaccinees (n=15) were 364 analzyed for IgG reactivity to viral homologues VAC A33R and mpox A35R. Mpox confirmed donors 365 were separated by birth year to simulate vaccination status before infection. Green circles indicate 366 recent vaccinees. Grey circles indicate a birth year prior to 1972 (childhood vaccine), and blue circles 367 indicate a birth year after 1972 (unvaccinated). Red circles in both groups indicate individuals infected 368 in the 2003 mpox outbreak. The dashed line in each plot indicates the reactivity cutoff for the indicated 369 antigen as determined by ROC curve. (D) Serum IgG reactivity ratio representing the mpox A35R MFI 370 divided by the VAC A33R MFI. Green circles indicate recent vaccinees. Grey circles indicate a birth 371 year prior to 1972 (childhood vaccine), and blue circles indicate a birth year after 1972 (unvaccinated). 372 Red circles in both groups indicate individuals infected in the 2003 mpox outbreak. Statistical 373 significance was determined by the non-parametric Kruskal-Wallis test where p < 0.05 *p < 0.001 **p374 < 0.0001, and ****p < 0.00001 adjusted for multiple comparisons by Dunn's test. 375

377 Main Text References

378

Rimoin AW, Kisalu N, Kebela-Ilunga B, Mukaba T, Wright LL, Formenty P, Wolfe ND, Shongo
 RL, Tshioko F, Okitolonda E, et al. (2007). Endemic human monkeypox, Democratic Republic of
 Congo, 2001-2004. Emerg Infect Dis 13, 934-937. 2007/06/08.

Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, Blumberg
S, Thomassen HA, Pike BL, Fair JN, et al. (2010). Major increase in human monkeypox incidence 30
years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl
Acad Sci U S A 107, 16262-16267. 2010/09/02.

386 3. Huang Y, Mu L and Wang W. (2022). Monkeypox: epidemiology, pathogenesis, treatment and 387 prevention. Signal Transduct Target Ther 7, 373. 2022/11/03.

Yinka-Ögunleye A, Aruna O, Dalhat M, Ogoina D, McCollum A, Disu Y, Mamadu I, Akinpelu A,
Ahmad A, Burga J, et al. (2019). Outbreak of human monkeypox in Nigeria in 2017-18: a clinical and
epidemiological report. Lancet Infect Dis 19, 872-879. 2019/07/10.

Gross E. (2003). Update on emerging infections: news from the Centers for Disease Control
and prevention. Update: Multistate outbreak of monkeypox--Illinois, Indiana, Kansas, Missouri, Ohio,
and Wisconsin, 2003. Ann Emerg Med 42, 660-662; discussion 662- 664. 2003/10/29.

6. Hendrickson RC, Wang Č, Hatcher EL and Lefkowitz EJ. (2010). Orthopoxvirus genome evolution: the role of gene loss. Viruses 2, 1933-1967. 2011/10/14.

396 7. Grabenstein JD and Winkenwerder W, Jr. (2003). US military smallpox vaccination program
 397 experience. JAMA 289, 3278-3282. 2003/06/26.

Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, Hauer J, Layton M,
 McDade J, Osterholm MT, et al. (1999). Smallpox as a biological weapon: medical and public health
 management. Working Group on Civilian Biodefense. JAMA 281, 2127-2137. 1999/06/15.

9. Payne AB, Ray LC, Cole MM, Canning M, Houck K, Shah HJ, Farrar JL, Lewis NM, Fothergill A,
White EB, et al. (2022). Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine
Compared with Risk Among Unvaccinated Persons - 43 U.S. Jurisdictions, July 31-October 1, 2022.
MMWR Morb Mortal Wkly Rep 71, 1560-1564. 2022/12/09.

405 10. Karem KL, Reynolds M, Hughes C, Braden Z, Nigam P, Crotty S, Glidewell J, Ahmed R, Amara
406 R and Damon IK. (2007). Monkeypox-induced immunity and failure of childhood smallpox vaccination
407 to provide complete protection. Clin Vaccine Immunol 14, 1318-1327. 2007/08/24.

Priyamvada L, Carson WC, Ortega E, Navarra T, Tran S, Smith TG, Pukuta E, Muyamuna E,
Kabamba J, Nguete BU, et al. (2022). Serological responses to the MVA-based JYNNEOS monkeypox
vaccine in a cohort of participants from the Democratic Republic of Congo. Vaccine 40, 7321-7327.
2022/11/08.

Townsend MB, Keckler MS, Patel N, Davies DH, Felgner P, Damon IK and Karem KL. (2013).
Humoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and
clinical correlations. J Virol 87, 900-911. 2012/11/09.

Alzhanova D, Hammarlund E, Reed J, Meermeier E, Rawlings S, Ray CA, Edwards DM, Bimber
B, Legasse A, Planer S, et al. (2014). T cell inactivation by poxviral B22 family proteins increases viral
virulence. PLoS Pathog 10, e1004123. 2014/05/17.

418 14. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, Hanifin JM and
419 Slifka MK. (2003). Duration of antiviral immunity after smallpox vaccination. Nat Med 9, 1131-1137.
420 2003/08/20.

421 15. Dubois ME, Hammarlund E and Slifka MK. (2012). Optimization of peptide-based ELISA for
422 serological diagnostics: a retrospective study of human monkeypox infection. Vector Borne Zoonotic
423 Dis 12, 400-409. 2012/01/06.

424 16. Kava CM, Rohraff DM, Wallace B, Mendoza-Alonzo JL, Currie DW, Munsey AE, Roth NM,

425 Bryant-Genevier J, Kennedy JL, Weller DL, et al. (2022). Epidemiologic Features of the Monkeypox

426 Outbreak and the Public Health Response - United States, May 17-October 6, 2022. MMWR Morb

427 Mortal Wkly Rep 71, 1449-1456. 2022/11/11.

428 17. Mandrekar JN. (2010). Receiver operating characteristic curve in diagnostic test assessment. J 429 Thorac Oncol 5, 1315-1316. 2010/08/26. 430 18. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L and Ahmed R. (2003). Cutting edge: 431 long-term B cell memory in humans after smallpox vaccination. J Immunol 171, 4969-4973. 2003/11/11. 432 Hanna W and Baxby D. (2002). Studies in smallpox and vaccination. 1913. Rev Med Virol 12. 19. 433 201-209. 2002/07/19. 434 Gilchuk I, Gilchuk P, Sapparapu G, Lampley R, Singh V, Kose N, Blum DL, Hughes LJ, 20. 435 Satheshkumar PS, Townsend MB, et al. (2016). Cross-Neutralizing and Protective Human Antibody 436 Specificities to Poxvirus Infections. Cell 167, 684-694 e689. 2016/10/22. 437 Hammarlund E, Lewis MW, Carter SV, Amanna I, Hansen SG, Strelow LI, Wong SW, Yoshihara 21. 438 P. Hanifin JM and Slifka MK. (2005). Multiple diagnostic techniques identify previously vaccinated 439 individuals with protective immunity against monkeypox. Nat Med 11, 1005-1011. 2005/08/09. 440 Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, Eisenberg RJ, Hartmann CJ, 22. 441 Jackson DL, Kulesh DA, et al. (2004). Immunogenicity of a highly attenuated MVA smallpox vaccine 442 and protection against monkeypox. Nature 428, 182-185, 2004/03/12. 443 Lane HC, Masur H, Edgar LC, Whalen G, Rook AH and Fauci AS. (1983). Abnormalities of B-23. 444 cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl 445 J Med 309, 453-458. 1983/08/25. 446 Shirai A, Cosentino M, Leitman-Klinman SF and Klinman DM. (1992). Human immunodeficiency 24. 447 virus infection induces both polyclonal and virus-specific B cell activation. J Clin Invest 89, 561-566. 448 1992/02/01. 449 Prigent J, Jarossay A, Planchais C, Eden C, Dufloo J, Kok A, Lorin V, Vratskikh O, Couderc T, 25. 450 Bruel T, et al. (2018). Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers 451 Polyreactivity. Cell Rep 23, 2568-2581. 2018/05/31. 452 26. Duke-Cohan JS, Wollenick K, Witten EA, Seaman MS, Baden LR, Dolin R and Reinherz EL. 453 (2009). The heterogeneity of human antibody responses to vaccinia virus revealed through use of 454 focused protein arrays. Vaccine 27, 1154-1165. 2009/01/17. 455 27. Lantto J, Haahr Hansen M, Rasmussen SK, Steinaa L, Poulsen TR, Duggan J, Dennis M, 456 Naylor I, Easterbrook L, Bregenholt S, et al. (2011). Capturing the natural diversity of the human 457 antibody response against vaccinia virus. J Virol 85, 1820-1833. 2010/12/15. 458 Yefet R, Friedel N, Tamir H, Polonsky K, Mor M, Cherry-Mimran L, Taleb E, Hagin D, Sprecher 28. 459 E, Israely T, et al. (2023). Monkeypox infection elicits strong antibody and B cell response against 460 A35R and H3L antigens. iScience 26, 105957. 2023/01/24. 461 Styer LM, Hoen R, Rock J, Yauney E, Nemeth K, Bievenue R and Parker MM. (2021). High-29. 462 Throughput Multiplex SARS-CoV-2 IgG Microsphere Immunoassay for Dried Blood Spots: A Public 463 Health Strategy for Enhanced Serosurvey Capacity. Microbiol Spectr 9, e0013421. 2021/07/29. 464 Reynolds SE and Moss B. (2015). Characterization of a large, proteolytically processed cowpox 30. 465 virus membrane glycoprotein conserved in most chordopoxviruses. Virology 483, 209-217. 2015/05/20. 466 Sereewit J, Lieberman NAP, Xie H, Bakhash S, Nunley BE, Chung B, Mills MG, Roychoudhury 31. 467 P and Greninger AL. (2022). ORF-Interrupting Mutations in Monkeypox Virus Genomes from 468 Washington and Ohio, 2022. Viruses 14. 2022/11/12. 469

470 Materials and Methods

471

472 Experimental Model and Subject Details

473 Human Subjects

- 474 This assay development study was performed using deidentified sera and plasma for a public health
- 475 function in a declared Public Health Emergency (PHE). It has been deemed "Non-human subject
- 476 research" by the NYS Institutional Review Board.
- 477 Biospecimens provided by the Icahn School of Medicine at Mount Sinai from the Personalized Virology
- 478 Initiative were reviewed and approved by the Mount Sinai Hospital Institutional Review Board (IRB-16-
- 479 16772 and IRB-16-00791). All participants provided written informed consent before specimens and
- 480 clinical information were collected. All specimens were coded before processing and analysis.

481 Specimen Collection

- 482 Whole blood in a red top/SST or equivalent tube, specimens allowed to clot at room temperature,
- 483 centrifuged and transferred serum into plastic tube(s), with storage refrigerated at 2-8°C prior to
- 484 shipment on freezer

485 Mpox-Negative Cohort

- 486 <u>Healthy-Normal</u>
- 487 Wadsworth Center employees volunteered serum specimens for assay development (n=114); 59 were
- 488 born prior to 1972 and 55 born after 1972. Normal Healthy Serum Pre-COVID-19 Pandemic Panel E
- 489 was purchased from Access Biologicals (n=85); 85 were born prior to 1972 and 66 born after 1972 with
- 490 military status unknown.
- 491 <u>*HIV*+</u>
- 492 One hundred and fourty-three (142) remnant plasma and serum specimens submitted for HIV
- diagnostic testing to the Wadsworth Center between 1/1/2018 and 12/31/2021. Specimens were
- 494 submitted for a variety of reasons, including confirmation of a reactive result on an HIV rapid test, to
- 495 resolve discordant HIV test results, or to verify a previous HIV diagnosis. HIV status was 'HIV-1
- 496 antibody positive for 131 (92%) and 'HIV antibody negative for 12 (8%) of the specimens. Specimens
- 497 were collected from individuals born either prior to 1972 (n=42) or after 1980 (n=100).

498 Mpox-Confirmed Cohort

- 499 The mpox-confirmed cohort (n = 40) is composed of specimens collected during the 2003 and 2022
- 500 United States outbreaks (**Table 1; Supplemental Figure 1**).
- 501 <u>2003 Outbreak</u>
- 502 Eighteen (18) of the 40 samples were collected following the 2003 mpox outbreak in the United States
- at approximately 6 months post-infection as previously described²¹. Eight out of 18 donors (44%)

received childhood smallpox immunization. The 2003 cohort was 66% female with an average age of

- 505 33 years at serum collection²¹.
- 506 <u>2022 Outbreak</u>
- 507 Twenty-two (22) of the 40 samples were collected during the 2022 mpox outbreak. In total, the group
- 508 was 90% male with an average age of 40 years at specimen collection.
- 509 Two (2) serum specimens were submitted to the Wadsworth Center Biodefense Laboratory for mpox
- 510 diagnostic testing on days 9 and 15 post-symptom onset, respectively. Mpox diagnosis was confirmed
- 511 by PCR assay.
- 512 At the Zucker School of Medicine at Hofstra/Northwell, serum was collected from 13 persons with
- 513 confirmed mpox infection, as defined by a positive PCR assay result. Specimens were de-identified and
- 514 the data collected included age, gender, date of mpox symptom onset, date of PCR positive test, name
- 515 of PCR assay used, VAC vaccination history, and date of serum collection.
- 516 At the Icahn School of Medicine at Mt. Sinai, serum was collected from 7 persons with confirmed mpox
- 517 infection by PCR assay. Specimens were de-identified and the shared data included age range,
- 518 gender, days since symptom onset, and VAC vaccination history.

519 Recent Vaccinee Cohort

- 520 The vaccinee cohort is composed of 5 serum specimens from Wadsworth Center employee donors
- 521 who were vaccinated with JYNNEOS® (day 56 post-primary inoculation), and 10 serum specimens
- 522 provided by donors from The Ican School of Medicine at Mt. Sinai that were vaccinated with
- 523 JYNNEOS® (n=8) or ACAM 2000 (n=2). All serum specimens used for analysis were collected at least
- 524 20 days following the last dose of vaccine.
- 525

526 Expression, Production, and Purification of Antigens

527 Production of B21/22R Peptides

528 Peptides were manufactured and supplied by Aalto Bio Reagents, Biosynth Group. The sequences for 529 peptides MPV B21R-A and -B, and VM B22R-A and B, were described in Dubois et. al.¹⁵ MPV B21R-A 530 and B correspond to B21R.179/180 and B21R.185/186, respectively. VM B22R-A and B correspond to 531 B22R.64/65 and B22R.82/83, respectively. Peptide produced using standard Fmoc-based solid phase 532 synthesis and purified using reverse phase high-performance liquid chromatography (RP-HPLC) to 533 >90% pure as determined by HPLC and/or LC/MS. Conjugation to BSA occurred through the side chain 534 of cysteine via sylfhydryl chemistry by mixing peptides with maleimide-activated BSA for two hours at

- 535 room temperature.
- 536

537 Recombinant OPV Antigens

538 Recombinant proteins were obtained from several commercial sources. Recombinant A27L (VAC-WR-539 A27L; NR 2213), A33R (VAC-WR-A33R; NR545), B5R (VAC-WR-B5R; NR-546) and L1R (VAC-WR-540 L2R; NR-21986) were obtained from BEI Resources, Manassas VA. Recombinant mpox A35R (230-541 30238) and mpox H3L (230-30233) were purchased from Ray Biotech, Peachtree Corners, GA. Mpox 542 A29L was produced by the Wadsworth Center Protein Expression Core. The mpox A29L gene 543 (GenBank: AY160186) subcloned into the plasmid pETMPOX/A27Lo-His6 was obtained from bei 544 Resources (Catalog # NR-3022). The construct was transformed into BL21(DE3)pLysS (Novagen) and expressed in Luria Broth containing 30 µg/mL kanamycin. Cell pellets were lysed in 50 mM Tris HCl. 545 546 300 mM NaCl, 10 mM imidazole, 0.1% Triton X100, 10% sucrose pH 7.5 containing EDTA-free 547 Complete Protease inhibitor (Roche) and 50 U Benzonase (Novagen). Cleared lysate was applied to a 548 1 ml HisTrap HP column (Cytiva) in 50 mM Tris HCl, 150 mM NaCl, 10% glycerol pH 7.5, washed with 549 50 mM Tris HCl, 1 M NaCl, 0.25 M arginine pH 8.5, and eluted with a linear gradient over 20 column 550 volumes to 50 mM Tris HCl, 150 mM NaCl, 10% glycerol, 500 mM imidazole pH 7.5. Fractions 551 containing protein were pooled and dialyzed against 50 mM Tris HCl, 150 mM NaCl, 10% glycerol, 1 552 mM EDTA pH 7.5 and then twice against a large excess of phosphate-buffered saline (PBS). The 553 protein was checked for size (16.4 kDa) and purity by sodium dodecyl sulfate polyacrylamide 554 electrophoresis (SDS-PAGE).

555

556 **OPV-specific Multiplex Microsphere Immunoassay (MIA)**

557 Specimens were assessed for the presence of antibodies reactive to OPV antigens using an MIA. 558 Recombinant proteins were covalently linked to the surface of fluorescent, magnetic microspheres 559 (Luminex Corporation). Serum or plasma samples (25 µl at 1:100 dilution) and antigen-coupled 560 microspheres (25 µl at 5x10⁴ microspheres/mL) were mixed and incubated for 30 minutes at 37°C. 561 Serum-bound microspheres were washed and incubated with phycoerythrin (PE)-conjugated secondary 562 antibody specific for human IgG (Southern Biotech). After washing and final resuspension in buffer, the 563 samples were analyzed on a FlexMap 3D analyzer using xPONENT software, version 4.3 (Luminex 564 Corporation).

Cohort	Number	Naïve (#)	VAC (#)	Age (yrs)	М	F	UNK	Day
Mpox-Confirmed	40	27	13	37	26	13	1	9 - 180
(Total)	40	21	15	57	20	15	I	3 - 100
2003	18	10	8	33	6	12	0	180
2022	22	17	5	40	20	1	1	9 -107
Mpox-Negative	244	221	121	40	170	170	1	n/a
(Total)	341							
Healthy	199	121	78	43	49	150	0	n/a
HIV	142	100	42	37	121	20	1	n/a
Recent	15	13	2	38	14	1	0	25 - 88
Vaccinees	15	13	2	50	14	I	0	20 - 00
Specificity Panel	115	-	-	-	-	-	115	n/a

Table 1: Cohorts Used for the Mpox	Serological Assay Development
------------------------------------	-------------------------------

Table 2: Diagnostic Performance of OPV Peptides and Antigens						
Antigen	ROC AUC	Cutoff (MFI)	Sensitivity % (95% Cl)	Specificity % (95% Cl)		
Mpox B21R-A	0.85	795	93% (80 – 97)	67% (62 – 72)		
Mpox B21R-B	0.85	602	85% (70 – 94)	75% (70 – 79)		
VAR B22R-A	0.56	1466	66% (48 – 80)	52% (47 – 57)		
VAR B22R-B	0.77	1828	81% (65 – 91)	72% (68 – 77)		
VAC A27L	0.75	678	88% (72 -95)	61% (55 – 66)		
Mpox A29L	0.77	960	84% (68 – 93)	59% (54 – 64)		
VAC A33R	0.96	8469	91% (77 – 97)	91% (88 – 94)		
Mpox A35R	0.97	7950	97% (85 – 100)	89% (85 – 92)		
VAC B5R	0.90	3353	94% (81 – 99)	82% (78 – 86)		
VAC L1R	0.81	711	65% (48 – 79)	84% (80 - 88)		
Mpox H3L	0.96	6927	97% (85 – 100)	90% (86 – 93)		

Sensitivity	Specificity	PPV [*]	95% Cl‡	NPV [†]	95% Cl‡
93%	98%	0.84	0.71 – 0.92	0.99	0.97 – 1.00
93%	100%	1.00	0.90 – 1.00	0.99	0.96 – 1.00
93%	94%	0.84	0.71 – 0.92	0.97	0.93 – 0.99
93%	93%	0.80	0.67 – 0.89	0.98	0.93 – 0.99
93%	98%	0.77	0.63 – 0.87	0.99	0.98 – 1.00
	93% 93% 93% 93%	93% 98% 93% 100% 93% 94% 93% 93%	93% 98% 0.84 93% 100% 1.00 93% 94% 0.84 93% 93% 0.80	93% 98% 0.84 0.71 - 0.92 93% 100% 1.00 0.90 - 1.00 93% 94% 0.84 0.71 - 0.92 93% 94% 0.84 0.71 - 0.92 93% 94% 0.84 0.71 - 0.92 93% 93% 0.80 0.67 - 0.89	93% 98% 0.84 0.71 - 0.92 0.99 0.93% 100% 1.00 0.90 - 1.00 0.99 0.93% 94% 0.84 0.71 - 0.92 0.97 0.93% 93% 0.80 0.67 - 0.89 0.98 0.98

Table 3: Sensitivity and Specificity of the NYS-OPV-MIA Based on Age Group

* Positive Predictive Value

†Negative Predictive Value

‡ Confidence Interval

569

Supplemental Table 1: Specificity Panel for Cross-Reactivity Testing
of the NYS-OPV-MIA

Antibody Positive Sera	Number Tested	Positive (R)	Negative (NR)	
Anti-nuclear antibody (ANA)	5	0	5	
Anaplasma phagocytophilum	3	1	2	
Bartonella spp.	1	0	1	
Borrelia burgdorferi	7	0	7	
Brucella spp.	3	0	3	
California Serogroup Viruses	4	0	4	
Cytomegalovirus	5	1	4	
Coxiella burnetii	3	0	3	
Dengue Virus	3	0	3	
Epstein-Barr Virus (EBV)	3	0	0	
Ehrlichia chaffeensis	3	0	3	
Enterovirus	2	0	2	
Hepatitis B Virus	1	1	0	
Hepatitis C Virus	2	0	2	
HIV1	2	0	2	
Herpes Simples Virus	13	0	13	
Measles	5	0	5	
Mumps	3	0	3	
Varicella-Zoster	18	0	18	
Parvovirus	3	0	3	
Powassan Virus	3	0	3	
Rheumatoid factor (RF)	2	0	2	
Rickettsia spp.	2	0	2	
Rubella	2	0	2	
Syphilis	8	0	8	
Western/Eastern Equine Encephalitis virus	1	0	1	
West Nile Virus	6	1	5	
Yellow Fever Virus	1	0	1	
Zika Virus	2	0	2	

571




Figure 1: Evaluation of Non-Vaccinia Peptides for the Detection of Mpox Infection

Serum or plasma specimens from 341 presumed mpox-negative donors and 40 mpox confirmed patients were analyzed for antibody reactivity to peptide antigens derived from mpox and variola virus (VAR) by a microsphere immunoassay. (A) Median fluorescence intensity (MFI) of IgG reactivity to individual 31-mer peptides was used to generate ROC curves representing for mpox-derived B21R-A and -B (magenta) or VAR-derived B22R-A and -B (blue). (B) The log10 MFI of IgG reactivity to mpox B21R-A and -B was plotted for mpox-negative, -positive, and vaccine control donors. The mpox-negative cohort was divided by birth year post- (presumed naive) and pre-1972 (Childhood VAC) to estimate smallpox childhood vaccination status. (C) Log10 MFI of IgG reactivity to mpox B21R-A and -B was plotted for mpox-negative to mpox B21R-A and -B was plotted by "healthy" and "HIV". Each dot represents and individual donor. Statistical significance was determined by the non-parametric Kruskal-Wallis test where *p < 0.05 **p < 0.001 ***p < 0.0001, and ****p < 0.00001 adjusted for multiple comparisons by Dunn's test.

Α.



Recombinant OPV Antigens 100 Mpox A35R 80 --- VV A33R Sensitivity (%) Mpox H3L 60 - - · VV B5R 40 -- · VV L1R Mpox A29L 20 --- VV A27L 0 0 20 40 60 80 100 Specificity (%)




Figure 2: Evaluation of Orthopoxvirus Antigens for the Detection of Mpox Infection

Serum or plasma specimens from 341 presumed mpox-negative donors and 40 mpox confirmed patients were analyzed for antibody reactivity to recombinant protein antigens derived from mpox or vaccinia virus (VAC) by microsphere immunoassay. **(A)** Median fluorescence intensity (MFI) of IgG reactivity to recombinant antigens from mpox or VAC (mpox A35R, solid magenta; VAC A33R, dashed magenta; mpox H3L solid light blue; VAC B5R dashed green; VAC L1R dashed orange; mpox A29L solid dark blue, VAC A27L dashed dark blue) were used to generate ROC curves used to represent the sensitivity (%) and specificity (%) of each antigen to detect mpox infection. (B) Log10 MFI of IgG reactivity to OPV antigens (A33/35, B5R, L1R, and H3L) plotted for mpox-negative, -positive, and recent vaccinee donors. Each dot represents and individual donor. Statistical significance was determined by the non-parametric Kruskal-Wallis test where *p < 0.05 **p < 0.001 ***p < 0.0001, and ****p < 0.0001 adjusted for multiple comparisons by Dunn's test.






Figure 3: Distribution of OPV Antigen and Mpox Peptide Reactivity Among Negative and Mpox Cohorts

Heat maps indicate the relative index value (MFI/cutoff value) of each antigen (Mpox A35R, VV B5R, VV L1R, Mpox H3L, Mpox B21R-A, and Mpox B21R-B; vertical columns) for each serum/plasma donor (horizon-tal rows). Yellow corresponds to a negative index value (< 1.0) below the clinical cutoff. The degree of red saturation corresponds to higher index values (> 1.0) above the clinical cutoff.

Β.









Figure 4: OPV Antigen Count and Algorithm for the New York State Orthopoxvirus (non-vaccinia) Microsphere Immunoassay for IgG Antibody Detection

(A) The number of OPV antigens (A33/35, B5R, L1R, and H3L) counted as reactive (R). Reactivity was defined as an MFI value at or above the calculated clinical cutoff value. The antigen count distribution was displayed as a violin plot for mpox-confirmed and mpox-negative cohorts. The mpox-negative cohort divided by birth year post- (presumed naïve) and pre-1972 (Childhood VAC) to estimate smallpox childhood vaccination status. (B) Serum or plasma specimens tested for mpox infection using a multiplexed microsphere immunoassay will be subjected to a 2-tier algorithm using a combination of mpox-specific peptides and OPV antigens. First, specimens will be considered for IgG reactivity to a set of cross-reactive OPV antigens (VAC A33R, mpox A35R, VAC B5R, VAC L1R, and mpox H3L). Samples with reactivity to 2 or fewer antigens will be considered non-reactive (NR; MFI < clinical cutoff) overall for mpox exposure while samples that test reactive (R; MFI > clinical cutoff) to 3 or more OPV antigens will move to the second tier of the algorithm. Next, samples will be considered for their reactivity to mpox peptides B21R-A and -B. Samples with no peptide reactivity will be considered NR for mpox infection. Samples with reactivity to one or more mpox peptides will be considered R for mpox infection. (C) Serum specimens from mpox-confirmed donors (n=40) and recent vaccinees (n=15) were analyzed for IgG reactivity to viral homologues VAC A33R and mpox A35R. Mpox confirmed donors were separated by birth year to simulate vaccination status before infection. Green circles indicate recent vaccinees. Grey circles indicate a birth year prior to 1972 (childhood vaccine), and blue circles indicate a birth year after 1972 (unvaccinated). Red circles in both groups indicate individuals infected in the 2003 mpox outbreak. The dashed line in each plot indicates the reactivity cutoff for the indicated antigen as determined by ROC curve. (D) Serum IgG reactivity ratio representing the mpox A35R MFI divided by the VAC A33R MFI. Green circles indicate recent vaccinees. Grey circles indicate a birth year prior to 1972 (childhood vaccine), and blue circles indicate a birth year after 1972 (unvaccinated). Red circles in both groups indicate individuals infected in the 2003 mpox outbreak. Statistical significance was determined by the non-parametric Kruskal-Wallis test where *p < 0.05 **p < 0.001 ***p < 0.0001, and ****p < 0.00001 adjusted for multiple comparisons by Dunn's test.



Supplemental Figure 1: Distribution of Days Post-Onset for Mpox-Confirmed Cohort

Histogram represents the number of specimens/donors at each day post-onset for the mpox-confirmed cohort. The 18 specimens at 180 days post-onset are from the 2003 group and the remainder of specimens are from the 2022 outbreak.